ArticleNPJ Parkinson's disease2025
A report of the Iranian Parkinson's disease registry.
Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Millions of people worldwide suffer from Parkinson's disease (PD), which has a varying distribution and features in each country. Since there is a shortage of data regarding PD patients in Iran, we present a registry-based study to deepen our understanding of Iranian PD patients' characteristics, distribution, and clinical differences between genders and different ages of onset. In six years, 4048 patients were interviewed, who had a mean age of 67.66 years, and consisted of 1474 (36.4%) females and 2571 (63.5%) males. Men suffered more from apathy, speech, handwriting, and salivation, while women experienced more anxiety, depression, pain, and psychosis, after multivariable regression. Early-onset Parkinson's disease (EOPD) and late-onset Parkinson's disease (LOPD) were divided based on the 50-year-old cut-off age. They were represented by 989 (24.6%) and 2834 (70%) of the total, respectively, and EOPD patients had a higher duration of the disease and a higher positive family history.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.